Key Highlights

  • Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) rose 29.68% after third quarter Revenue climbed 44% to USD 107.2 million and the 2030 revenue outlook was lifted above USD 1 billion.
  • Vericel Corporation (NASDAQ:VCEL) gained 20.27% after revenue grew 26% to USD 85.4 million and full-year guidance was raised to USD 344 million to USD 346 million.
  • ADMA Biologics, Inc. (NASDAQ:ADMA) rallied 25.52% as ASCENIV revenue rose 31% to USD 124.7 million, while total revenue grew only 5% to USD 141.1 million.
  • Arq rose 30.28% after a USD 2.5 million profit, and CareCloud rose 23.33% after reporting what it called its most profitable quarter.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Raised Guidance and a Bigger 2030 Target

The strongest reaction came at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), up 29.68% to USD 13.57 in trading on November 5, 2026, per published market data, after third quarter results released the same day. Revenue rose 44% to USD 107.2 million from USD 74.4 million, led by Recorlev, a Cushing's syndrome treatment, which rose 93% to USD 71.5 million. Net Income was USD 11.3 million against USD 0.6 million, and adjusted EBITDA was USD 30.8 million. The company raised 2026 revenue guidance to USD 395 million to USD 405 million and its 2030 outlook to more than USD 1 billion from about USD 750 million. Not every line grew: Gvoke fell 14% to USD 21.7 million, including a one-time gross-to-net adjustment of about USD 4 million. Recorlev produced about two-thirds of revenue on simple arithmetic, so concentration is the main risk. Long-term Debt was USD 189.7 million against cash of USD 131.1 million, and a 2030 target is an ambition rather than a contract.

ADMA Biologics, Inc. (NASDAQ:ADMA): Profit Growing Faster Than Sales

At ADMA Biologics, Inc. (NASDAQ:ADMA), the shares rose 25.52% to USD 13.16 after results released November 4, 2026. Revenue was USD 141.1 million, up 5%, but ASCENIV, its immune globulin for primary immunodeficiency, rose 31% to USD 124.7 million while older BIVIGAM fell 35% to USD 15.4 million. GAAP net income climbed 37% to USD 49.9 million and adjusted EBITDA rose 32% to USD 77.3 million. The company raised adjusted net income guidance to at least USD 180 million and adjusted EBITDA guidance to at least USD 275 million, and reiterated revenue of at least USD 530 million; the size of the raise is not verified against prior minimums. A mix shift toward higher-priced ASCENIV explains why profit outran sales. Buybacks of 16.5 million shares year to date have been partly funded by borrowing, with total debt of about USD 195.9 million on simple arithmetic. Dependence on one product and a modest 5% sales gain leave room for disappointment, and gains of this size can retrace.

Vericel Corporation (NASDAQ:VCEL): A Beat Across the Product Lines

The 20.27% climb at Vericel Corporation (NASDAQ:VCEL), to USD 54.70, followed third quarter results on November 5, 2026. Total net revenue rose 26% to USD 85.4 million from USD 67.5 million. MACI, the cartilage repair therapy, contributed USD 67.4 million, and the company reported its highest quarterly MACI Arthro case count since launch. Burn Care revenue rose 52% to USD 18.0 million, including USD 3.0 million of procurement revenue from the Biomedical Advanced Research and Development Authority. Net income rose 179% to USD 14.2 million and adjusted EBITDA Margin widened to 30% from 25%, the Operating Leverage typical of a specialty Biologics company with a mostly Fixed Cost base. Full-year revenue guidance rose to USD 344 million to USD 346 million from USD 330 million to USD 340 million. Cash was USD 235.6 million with no debt. The risks are valuation, with published market data implying a multiple near 118 on trailing earnings, and MACI concentration at about four fifths of revenue. Volume was below average, so a quoted gain can partly reverse.

Arq, Inc. (NASDAQ:ARQ): Margin Gains Behind a Small-Cap Jump

The 30.28% rise at Arq, Inc. (NASDAQ:ARQ), to USD 2.41 on about 29.6 times usual volume, followed third quarter results released November 4, 2026. Revenue rose to USD 38.2 million from USD 35.1 million, roughly 8.8% on simple arithmetic, while gross margin widened to 39.7% from 28.8%, which means each unit of revenue left more to cover fixed costs and explains the swing to a USD 2.5 million net profit, or USD 0.06 per diluted share. Adjusted EBITDA reached USD 8.8 million against USD 5.2 million. Guidance points to revenue of USD 120 million to USD 125 million and adjusted EBITDA of USD 19 million to USD 20 million, with the lower end of the EBITDA range raised. The Balance Sheet is less comfortable: cash was USD 19.1 million, of which USD 11.3 million is restricted, against debt of USD 28.2 million. Management has said PFAS treatment orders are not expected before 2027. As a small cap, a limited number of trades can move the price and quoted moves can reverse.

CareCloud, Inc. (NASDAQ:CCLD): A Record Profit Funded by Debt

At CareCloud, Inc. (NASDAQ:CCLD), the stock rose 23.33% to USD 2.22 after third quarter results on November 5, 2026, ahead of an 8:30 a.m. ET call. Revenue was USD 33.7 million, up 9%, GAAP net income rose 54% to USD 4.7 million and adjusted EBITDA reached USD 9.9 million, a 29% margin. Chief Executive Stephen Snyder called it the most profitable quarter in company history, and management reaffirmed 2026 guidance of USD 128 million to USD 132 million in revenue and USD 29 million to USD 31 million in adjusted EBITDA. Nine-month adjusted EBITDA of USD 21.2 million implies about USD 7.8 million to USD 9.8 million in the fourth quarter, simple arithmetic on published numbers. The company redeemed its Series B preferred stock on May 15, 2026 using a Credit facility, which removed a preferred Dividend but lifted loans to USD 37.3 million with cash of only USD 4.6 million. Shareholders' Equity fell to USD 22.6 million. With a micro-cap float and about 933,000 shares traded, quoted moves can reverse.

Where Things Stand

The evidence says these are mostly earned rallies: each company reported higher profit and either raised or reaffirmed guidance, though the quality and durability differ. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) and Vericel combined growth with raised outlooks. ADMA Biologics, Inc. (NASDAQ:ADMA) had profit growth far ahead of sales. Arq, Inc. (NASDAQ:ARQ) and CareCloud rose from smaller bases, with debt and thin Liquidity as counterweights. After moves of 20% to 30% in one session, expectations are higher and a quoted intraday gain can partly reverse. Nothing here implies the rise will continue. The next catalysts are fourth quarter reports, Recorlev prescription trends, MACI delivery against the new range and the CareCloud, Inc. (NASDAQ:CCLD) debt paydown.